Clinical Trial Update: Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Avastin (bevacizumab) with everolimus in advanced low or intermediate grade neuroendocrine carcinoma; results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Everolimus (everolimus)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2013-05-08